Literature DB >> 12591752

Myocardial proinflammatory cytokine expression and left ventricular remodeling in patients with chronic mitral regurgitation.

Hakan Oral1, Natarajan Sivasubramanian, David B Dyke, Rajendra H Mehta, P Michael Grossman, Kerri Briesmiester, William P Fay, Francis D Pagani, Steven F Bolling, Douglas L Mann, Mark R Starling.   

Abstract

BACKGROUND: In an animal model, stretch was shown to induce myocardial tumor necrosis factor-alpha (TNF-alpha) expression. The purposes of this study were to determine whether the left ventricular (LV) volume overload that occurs in patients with chronic mitral regurgitation (MR) can induce myocardial and systemic TNF-alpha expression and whether there is a relationship between TNF-alpha expression and LV remodeling. METHODS AND
RESULTS: Plasma TNF-alpha and its receptors were measured before mitral valve (MV) repair surgery in 26 MR patients and 23+/-12 months after MV repair surgery in 9 MR patients. Myocardial mRNA copies of TNF-alpha were determined in 11 MR and 10 donor hearts using quantitative RT-PCR. Compared with 15 control subjects, pre-MV repair plasma TNF-alpha (3.59+/-1.81 versus 2.03+/-1.02 pg/mL, P<0.005) and its receptor levels were elevated in MR patients. Myocardial TNF-alpha mRNA copies (corrected for beta-actin mRNA expression) in MR patients and donor hearts were 38.96+/-42.74x10(6) and 0.88+/-0.75x10(6), respectively (P=0.01). After MV surgery, there was a decrease in the plasma levels of TNF-alpha (2.79+/-1.14 versus 3.51+/-1.34 pg/mL, P=0.02) and its receptors. There was a correlation between myocardial TNF-alpha expression and preoperative LV end-diastolic and end-systolic volumes. Moreover, there was an inverse correlation between myocardial TNF-alpha expression and regression in LV end-diastolic (r=-0.76, P=0.007) and end-systolic (r=-0.73, P=0.01) volumes after MV surgery.
CONCLUSIONS: TNF-alpha is expressed in the myocardium and plasma of MR patients. Correction of the LV volume overload with MV surgery results in reversal of TNF-alpha expression. There is a relationship between TNF-alpha expression and parameters of LV remodeling, suggesting that TNF-alpha may play a role in the pathogenesis of the LV remodeling that occurs in MR.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12591752     DOI: 10.1161/01.cir.0000049745.38594.6d

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  21 in total

Review 1.  Tissue-Engineering for the Study of Cardiac Biomechanics.

Authors:  Stephen P Ma; Gordana Vunjak-Novakovic
Journal:  J Biomech Eng       Date:  2016-02       Impact factor: 2.097

2.  Increased oxidative stress and cardiomyocyte myofibrillar degeneration in patients with chronic isolated mitral regurgitation and ejection fraction >60%.

Authors:  Mustafa I Ahmed; James D Gladden; Silvio H Litovsky; Steven G Lloyd; Himanshu Gupta; Seidu Inusah; Thomas Denney; Pamela Powell; David C McGiffin; Louis J Dell'Italia
Journal:  J Am Coll Cardiol       Date:  2010-02-16       Impact factor: 24.094

3.  Plasma levels of tumor necrosis factor-alpha and its receptors in patients with mitral stenosis and sinus rhythm undergoing percutaneous balloon valvuloplasty.

Authors:  Kumral Ergun Cagli; Dursun Aras; Serkan Topaloglu; Bilal Geyik; Selime Ayaz; Goksel Cagirci; Halil Lutfi Kisacik; Sule Korkmaz
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

4.  Chymase inhibition prevents fibronectin and myofibrillar loss and improves cardiomyocyte function and LV torsion angle in dogs with isolated mitral regurgitation.

Authors:  Betty Pat; Yuanwen Chen; Cheryl Killingsworth; James D Gladden; Ke Shi; Junying Zheng; Pamela C Powell; Greg Walcott; Mustafa I Ahmed; Himanshu Gupta; Ravi Desai; Chih-Chang Wei; Naoki Hase; Tsunefumi Kobayashi; Abdelkarim Sabri; Henk Granzier; Thomas Denney; Michael Tillson; A Ray Dillon; Ahsan Husain; Louis J Dell'italia
Journal:  Circulation       Date:  2010-09-27       Impact factor: 29.690

5.  Inflammation in myocardial injury: mesenchymal stem cells as potential immunomodulators.

Authors:  Weiang Yan; Ejlal Abu-El-Rub; Sekaran Saravanan; Lorrie A Kirshenbaum; Rakesh C Arora; Sanjiv Dhingra
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-24       Impact factor: 4.733

Review 6.  Role of oxidative stress in disease progression in Stage B, a pre-cursor of heart failure.

Authors:  Arvind Bhimaraj; W H Wilson Tang
Journal:  Heart Fail Clin       Date:  2011-10-22       Impact factor: 3.179

7.  Increased sarcolipin expression and adrenergic drive in humans with preserved left ventricular ejection fraction and chronic isolated mitral regurgitation.

Authors:  Junying Zheng; Danielle M Yancey; Mustafa I Ahmed; Chih-Chang Wei; Pamela C Powell; Mayilvahanan Shanmugam; Himanshu Gupta; Steven G Lloyd; David C McGiffin; Chun G Schiros; Thomas S Denney; Gopal J Babu; Louis J Dell'Italia
Journal:  Circ Heart Fail       Date:  2013-12-02       Impact factor: 8.790

8.  Disruption of desmin-mitochondrial architecture in patients with regurgitant mitral valves and preserved ventricular function.

Authors:  Mustafa I Ahmed; Jason L Guichard; Rajasekaran Namakkal Soorappan; Shama Ahmad; Nithya Mariappan; Silvio Litovsky; Himanshu Gupta; Steven G Lloyd; Thomas S Denney; Pamela Cox Powell; Inmaculada Aban; James Collawn; James E Davies; David C McGiffin; Louis J Dell'Italia
Journal:  J Thorac Cardiovasc Surg       Date:  2016-06-25       Impact factor: 5.209

9.  Genetically altered mutant mouse models of guanylyl cyclase/natriuretic peptide receptor-A exhibit the cardiac expression of proinflammatory mediators in a gene-dose-dependent manner.

Authors:  Elangovan Vellaichamy; Subhankar Das; Umadevi Subramanian; Nobuyo Maeda; Kailash N Pandey
Journal:  Endocrinology       Date:  2014-01-01       Impact factor: 4.736

Review 10.  Regulation of cardiac angiotensin-converting enzyme and angiotensin AT1 receptor gene expression in Npr1 gene-disrupted mice.

Authors:  Kailash N Pandey; Elangovan Vellaichamy
Journal:  Clin Exp Pharmacol Physiol       Date:  2009-10-16       Impact factor: 2.557

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.